 Carlos Catalano
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteriophage lambda | 52 | 2025 | 90 | 9.790 |
Why?
| | Virus Assembly | 36 | 2025 | 81 | 8.080 |
Why?
| | DNA, Viral | 36 | 2025 | 358 | 4.930 |
Why?
| | DNA Packaging | 18 | 2025 | 24 | 4.880 |
Why?
| | Endodeoxyribonucleases | 32 | 2025 | 78 | 4.180 |
Why?
| | Genome, Viral | 17 | 2020 | 218 | 3.280 |
Why?
| | Capsid Proteins | 10 | 2022 | 95 | 3.090 |
Why?
| | Capsid | 14 | 2022 | 94 | 2.880 |
Why?
| | Viral Proteins | 21 | 2019 | 355 | 2.440 |
Why?
| | Integration Host Factors | 10 | 2025 | 13 | 1.570 |
Why?
| | Nanoparticles | 4 | 2022 | 520 | 1.480 |
Why?
| | Adenosine Triphosphate | 17 | 2020 | 498 | 1.290 |
Why?
| | Glycoproteins | 5 | 2017 | 355 | 1.230 |
Why?
| | Molecular Motor Proteins | 5 | 2011 | 46 | 1.040 |
Why?
| | Adenosine Triphosphatases | 14 | 2019 | 162 | 0.960 |
Why?
| | Protein Folding | 8 | 2022 | 279 | 0.800 |
Why?
| | Models, Molecular | 12 | 2017 | 1619 | 0.690 |
Why?
| | Escherichia coli | 11 | 2025 | 855 | 0.690 |
Why?
| | Hydrolysis | 11 | 2019 | 199 | 0.680 |
Why?
| | Thermodynamics | 6 | 2015 | 426 | 0.670 |
Why?
| | Biological Products | 1 | 2022 | 252 | 0.570 |
Why?
| | Breast Neoplasms | 2 | 2022 | 2456 | 0.570 |
Why?
| | DNA-Binding Proteins | 10 | 2005 | 1500 | 0.480 |
Why?
| | Protein Precursors | 1 | 2017 | 137 | 0.480 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2015 | 4 | 0.470 |
Why?
| | Nucleic Acid Conformation | 5 | 2015 | 726 | 0.460 |
Why?
| | DNA Helicases | 3 | 2011 | 143 | 0.450 |
Why?
| | AIDS Vaccines | 1 | 2015 | 52 | 0.450 |
Why?
| | Molecular Sequence Data | 13 | 2013 | 2931 | 0.400 |
Why?
| | Kinetics | 16 | 2012 | 1629 | 0.360 |
Why?
| | Escherichia coli Proteins | 2 | 2020 | 206 | 0.340 |
Why?
| | Catalysis | 7 | 2019 | 322 | 0.340 |
Why?
| | Trastuzumab | 2 | 2022 | 118 | 0.340 |
Why?
| | DNA | 6 | 2024 | 1464 | 0.330 |
Why?
| | Protein Subunits | 4 | 2006 | 226 | 0.330 |
Why?
| | DNA Viruses | 2 | 2012 | 23 | 0.320 |
Why?
| | Amino Acid Sequence | 9 | 2013 | 2157 | 0.320 |
Why?
| | Protein Multimerization | 3 | 2017 | 214 | 0.320 |
Why?
| | Protein Structure, Quaternary | 5 | 2019 | 116 | 0.320 |
Why?
| | Ultracentrifugation | 4 | 2017 | 51 | 0.300 |
Why?
| | Peptide Hydrolases | 1 | 2010 | 105 | 0.300 |
Why?
| | Protein Conformation | 9 | 2014 | 946 | 0.300 |
Why?
| | Nucleotides | 2 | 2008 | 128 | 0.290 |
Why?
| | Bacteriophages | 2 | 2024 | 111 | 0.290 |
Why?
| | Nucleocapsid | 1 | 2008 | 19 | 0.280 |
Why?
| | Nucleoproteins | 3 | 2019 | 38 | 0.270 |
Why?
| | Promoter Regions, Genetic | 4 | 2017 | 1258 | 0.270 |
Why?
| | DNA Replication | 3 | 2006 | 251 | 0.260 |
Why?
| | Models, Biological | 6 | 2015 | 1822 | 0.250 |
Why?
| | Protein Structure, Secondary | 4 | 2017 | 369 | 0.240 |
Why?
| | Mutation | 8 | 2019 | 4099 | 0.230 |
Why?
| | Biological Assay | 1 | 2006 | 128 | 0.230 |
Why?
| | DNA, Bacterial | 1 | 2006 | 342 | 0.220 |
Why?
| | Holoenzymes | 1 | 2005 | 25 | 0.220 |
Why?
| | Chest Pain | 1 | 2025 | 100 | 0.220 |
Why?
| | Proteomics | 2 | 2022 | 1195 | 0.220 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 2 | 2017 | 192 | 0.200 |
Why?
| | Cell Line, Tumor | 2 | 2022 | 3550 | 0.200 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 183 | 0.200 |
Why?
| | Binding Sites | 7 | 2016 | 1331 | 0.190 |
Why?
| | Dimerization | 4 | 2005 | 194 | 0.190 |
Why?
| | Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 4 | 0.190 |
Why?
| | GTP Phosphohydrolases | 2 | 2000 | 93 | 0.190 |
Why?
| | Radiology | 1 | 2025 | 175 | 0.180 |
Why?
| | Models, Chemical | 1 | 2004 | 269 | 0.180 |
Why?
| | Temperature | 4 | 2024 | 679 | 0.180 |
Why?
| | Protein Stability | 2 | 2013 | 178 | 0.180 |
Why?
| | Adenine Nucleotides | 1 | 2020 | 21 | 0.160 |
Why?
| | Base Sequence | 7 | 2000 | 2191 | 0.160 |
Why?
| | Acid Anhydride Hydrolases | 1 | 1999 | 7 | 0.160 |
Why?
| | AAA Domain | 1 | 2019 | 3 | 0.150 |
Why?
| | DNA Polymerase I | 2 | 1990 | 31 | 0.150 |
Why?
| | Cations, Divalent | 2 | 2012 | 47 | 0.150 |
Why?
| | Circular Dichroism | 4 | 2001 | 150 | 0.150 |
Why?
| | Bacterial Proteins | 5 | 2013 | 962 | 0.140 |
Why?
| | Sodium Chloride | 2 | 2015 | 142 | 0.140 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2011 | 346 | 0.140 |
Why?
| | Protein Domains | 2 | 2017 | 313 | 0.140 |
Why?
| | Protein Structure, Tertiary | 4 | 2010 | 862 | 0.140 |
Why?
| | Phosphates | 1 | 2019 | 180 | 0.140 |
Why?
| | Plasmids | 3 | 2014 | 379 | 0.130 |
Why?
| | Arginine | 1 | 2019 | 262 | 0.130 |
Why?
| | Substrate Specificity | 4 | 2013 | 392 | 0.130 |
Why?
| | Sequence Deletion | 3 | 2005 | 193 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2019 | 251 | 0.120 |
Why?
| | Static Electricity | 1 | 2017 | 113 | 0.120 |
Why?
| | Vaccines | 1 | 2022 | 389 | 0.120 |
Why?
| | Peptide Fragments | 2 | 1999 | 699 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 69 | 0.120 |
Why?
| | Molecular Weight | 3 | 2006 | 327 | 0.120 |
Why?
| | Area Under Curve | 1 | 2017 | 331 | 0.120 |
Why?
| | Lipase | 1 | 2016 | 75 | 0.120 |
Why?
| | Biomechanical Phenomena | 2 | 2017 | 842 | 0.120 |
Why?
| | Magnesium | 2 | 2012 | 155 | 0.120 |
Why?
| | Protein Binding | 5 | 2015 | 2276 | 0.120 |
Why?
| | Molecular Dynamics Simulation | 2 | 2019 | 260 | 0.120 |
Why?
| | RNA Nucleotidyltransferases | 1 | 1995 | 23 | 0.120 |
Why?
| | Acrolein | 1 | 1995 | 22 | 0.120 |
Why?
| | DNA Polymerase II | 1 | 1995 | 35 | 0.120 |
Why?
| | Italy | 2 | 2025 | 114 | 0.110 |
Why?
| | Protein Denaturation | 3 | 2001 | 75 | 0.110 |
Why?
| | Microscopy, Electron | 1 | 2015 | 415 | 0.110 |
Why?
| | Enzyme Stability | 3 | 1999 | 73 | 0.110 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2014 | 87 | 0.110 |
Why?
| | Genes, Bacterial | 1 | 2014 | 166 | 0.110 |
Why?
| | Biotechnology | 1 | 2014 | 46 | 0.100 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2006 | 561 | 0.100 |
Why?
| | Bacterial Secretion Systems | 1 | 2013 | 6 | 0.100 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 331 | 0.100 |
Why?
| | Cloning, Molecular | 3 | 1999 | 541 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2016 | 266 | 0.100 |
Why?
| | Validation Studies as Topic | 1 | 2013 | 23 | 0.100 |
Why?
| | Hemolysin Proteins | 1 | 2013 | 36 | 0.100 |
Why?
| | Herpesvirus 1, Human | 1 | 2014 | 84 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 2016 | 528 | 0.100 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2010 | 396 | 0.090 |
Why?
| | Recombinant Proteins | 3 | 2005 | 1371 | 0.090 |
Why?
| | Buffers | 2 | 2006 | 55 | 0.090 |
Why?
| | Drug Carriers | 1 | 2013 | 130 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2015 | 341 | 0.090 |
Why?
| | Ligands | 1 | 2014 | 674 | 0.090 |
Why?
| | Cross-Linking Reagents | 1 | 2013 | 207 | 0.090 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2014 | 328 | 0.090 |
Why?
| | Spectrometry, Fluorescence | 2 | 2005 | 168 | 0.090 |
Why?
| | Bacillus Phages | 1 | 2011 | 2 | 0.090 |
Why?
| | Gene Expression | 1 | 2017 | 1490 | 0.090 |
Why?
| | Urea | 1 | 2012 | 84 | 0.090 |
Why?
| | Genetic Variation | 1 | 2016 | 984 | 0.090 |
Why?
| | Lysine | 1 | 2013 | 302 | 0.080 |
Why?
| | Binding, Competitive | 2 | 2015 | 193 | 0.080 |
Why?
| | Adenoviridae | 1 | 2011 | 199 | 0.080 |
Why?
| | Polyamines | 2 | 2006 | 42 | 0.080 |
Why?
| | Pseudomonas aeruginosa | 1 | 2013 | 356 | 0.080 |
Why?
| | DNA Primers | 3 | 2001 | 512 | 0.080 |
Why?
| | DNA Probes | 1 | 1990 | 59 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2016 | 1167 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 750 | 0.080 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 84 | 0.080 |
Why?
| | Optical Tweezers | 2 | 2025 | 21 | 0.070 |
Why?
| | Proteins | 1 | 2015 | 1022 | 0.070 |
Why?
| | Humans | 9 | 2025 | 144957 | 0.070 |
Why?
| | Fluorescent Dyes | 1 | 1990 | 330 | 0.070 |
Why?
| | Muramidase | 2 | 2022 | 67 | 0.070 |
Why?
| | Liver | 1 | 2016 | 1888 | 0.070 |
Why?
| | Virion | 1 | 2008 | 111 | 0.070 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2001 | 85 | 0.070 |
Why?
| | Fluorescence | 1 | 2007 | 161 | 0.060 |
Why?
| | Azides | 2 | 2005 | 47 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2016 | 631 | 0.060 |
Why?
| | Virulence | 1 | 2007 | 280 | 0.060 |
Why?
| | Female | 4 | 2022 | 78376 | 0.060 |
Why?
| | Biophysical Phenomena | 2 | 2007 | 68 | 0.060 |
Why?
| | Acrylamide | 1 | 2005 | 3 | 0.060 |
Why?
| | Photoaffinity Labels | 1 | 2005 | 6 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2011 | 936 | 0.060 |
Why?
| | Biophysics | 2 | 2007 | 74 | 0.060 |
Why?
| | Macromolecular Substances | 2 | 1998 | 224 | 0.060 |
Why?
| | Single Molecule Imaging | 1 | 2025 | 46 | 0.050 |
Why?
| | Phage Therapy | 1 | 2024 | 17 | 0.050 |
Why?
| | Bone Cements | 1 | 2024 | 39 | 0.050 |
Why?
| | Computed Tomography Angiography | 1 | 2025 | 145 | 0.050 |
Why?
| | Vanadates | 1 | 2004 | 17 | 0.050 |
Why?
| | Tryptophan | 1 | 2005 | 181 | 0.050 |
Why?
| | Drug Compounding | 1 | 2024 | 107 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2025 | 323 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2005 | 402 | 0.050 |
Why?
| | Helix-Turn-Helix Motifs | 1 | 2002 | 5 | 0.050 |
Why?
| | Acute Disease | 1 | 2025 | 1031 | 0.050 |
Why?
| | Climate Change | 1 | 2025 | 199 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 536 | 0.050 |
Why?
| | Aluminum Oxide | 1 | 2022 | 13 | 0.050 |
Why?
| | Adenosine | 1 | 2004 | 255 | 0.040 |
Why?
| | Powders | 1 | 2022 | 44 | 0.040 |
Why?
| | False Negative Reactions | 1 | 2021 | 61 | 0.040 |
Why?
| | Societies, Medical | 1 | 2025 | 887 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 570 | 0.040 |
Why?
| | Nitrogen Isotopes | 1 | 2000 | 72 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2005 | 781 | 0.040 |
Why?
| | Genes, Viral | 3 | 1997 | 90 | 0.040 |
Why?
| | Protons | 1 | 2000 | 95 | 0.040 |
Why?
| | Carbon Isotopes | 1 | 2000 | 144 | 0.040 |
Why?
| | HIV Infections | 1 | 2015 | 3154 | 0.040 |
Why?
| | Nucleoside-Triphosphatase | 1 | 1999 | 14 | 0.040 |
Why?
| | Guanosine Triphosphate | 1 | 1999 | 89 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 1999 | 98 | 0.040 |
Why?
| | Endonucleases | 1 | 1999 | 34 | 0.040 |
Why?
| | Histidine | 1 | 1999 | 66 | 0.040 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1999 | 94 | 0.040 |
Why?
| | Catalytic Domain | 1 | 1999 | 234 | 0.040 |
Why?
| | Sarcosine | 1 | 1998 | 10 | 0.040 |
Why?
| | Guanidine | 1 | 1998 | 20 | 0.040 |
Why?
| | Detergents | 1 | 1998 | 44 | 0.030 |
Why?
| | Solutions | 1 | 1998 | 167 | 0.030 |
Why?
| | Hot Temperature | 1 | 2001 | 407 | 0.030 |
Why?
| | Solubility | 1 | 1998 | 242 | 0.030 |
Why?
| | Pseudomonas Phages | 1 | 1997 | 3 | 0.030 |
Why?
| | Terminator Regions, Genetic | 1 | 1997 | 13 | 0.030 |
Why?
| | Suppression, Genetic | 1 | 1997 | 26 | 0.030 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2016 | 18 | 0.030 |
Why?
| | Imidazoles | 1 | 1998 | 254 | 0.030 |
Why?
| | Carotid Artery, Common | 1 | 2016 | 31 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 75 | 0.030 |
Why?
| | Acyltransferases | 1 | 2016 | 78 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 102 | 0.030 |
Why?
| | Iodoacetamide | 1 | 1995 | 5 | 0.030 |
Why?
| | Dithiothreitol | 1 | 1995 | 19 | 0.030 |
Why?
| | DNA Primase | 1 | 1995 | 47 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1995 | 141 | 0.030 |
Why?
| | Point Mutation | 1 | 2016 | 243 | 0.030 |
Why?
| | Vero Cells | 1 | 2014 | 84 | 0.030 |
Why?
| | Receptors, Transferrin | 1 | 2013 | 28 | 0.030 |
Why?
| | Transferrin | 1 | 2013 | 50 | 0.030 |
Why?
| | Microscopy, Atomic Force | 1 | 2014 | 134 | 0.030 |
Why?
| | Virus Internalization | 1 | 2013 | 65 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1915 | 0.020 |
Why?
| | Amidohydrolases | 1 | 2013 | 32 | 0.020 |
Why?
| | Prognosis | 1 | 2022 | 4293 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2313 | 0.020 |
Why?
| | Restriction Mapping | 1 | 1993 | 80 | 0.020 |
Why?
| | Chromatography, Ion Exchange | 1 | 1993 | 57 | 0.020 |
Why?
| | Chromatography, Affinity | 1 | 1993 | 85 | 0.020 |
Why?
| | Materials Testing | 1 | 2014 | 354 | 0.020 |
Why?
| | Ultrasonography | 1 | 2016 | 770 | 0.020 |
Why?
| | Viral Plaque Assay | 1 | 2011 | 29 | 0.020 |
Why?
| | HeLa Cells | 1 | 2013 | 650 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2738 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2013 | 200 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2118 | 0.020 |
Why?
| | Bacteriophage T4 | 1 | 2010 | 18 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 577 | 0.020 |
Why?
| | Computer Graphics | 1 | 1990 | 41 | 0.020 |
Why?
| | Microspheres | 1 | 2010 | 142 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2010 | 224 | 0.020 |
Why?
| | Exodeoxyribonuclease V | 1 | 1989 | 6 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 526 | 0.020 |
Why?
| | Exodeoxyribonucleases | 1 | 1989 | 28 | 0.020 |
Why?
| | Lung | 1 | 2022 | 4109 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3164 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2365 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1839 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3676 | 0.020 |
Why?
| | Adult | 2 | 2021 | 40506 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 3869 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2005 | 418 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10792 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 2001 | 48 | 0.010 |
Why?
| | Virus Replication | 1 | 2001 | 529 | 0.010 |
Why?
| | Trypsin | 1 | 1997 | 76 | 0.010 |
Why?
| | Affinity Labels | 1 | 1996 | 25 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1996 | 381 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 35928 | 0.010 |
Why?
| | Animals | 1 | 2014 | 38109 | 0.010 |
Why?
| | Male | 1 | 2016 | 72406 | 0.000 |
Why?
|
|
Catalano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|